Superworth

Enanta Pharmaceuticals price to book ratio ENTA

Market value divided by the book value of the company's net assets, since 2013.

Today, Oct 23, 2026
3.4×
10-year median
2.6×
Against its 10-year history
69th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.7× to 7.5×
Peer median
1.9×

Enanta Pharmaceuticals' price to book ratio is 3.4× as of Oct 23, 2026.

That is above its ten-year median of 2.6×, higher than on 69% of days in the last ten years.

Over that time it ranged from 0.7× in Nov 2023 to 7.5× in Dec 2025.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.4×2.8×6.4×
20257.5×0.8×7.5×
20241.0×1.0×2.0×
20230.9×0.7×3.7×
20223.0×2.3×4.3×
20213.8×1.9×4.7×
20201.9×1.8×2.6×
20192.7×2.6×4.8×
20183.5×3.3×7.2×
20173.7×2.0×3.7×
20162.4×1.6×2.4×
20152.6×2.0×6.3×
20146.5×4.7×8.4×
20134.6×2.5×5.8×

Against its peers

Companies in Drug Manufacturers - General nearest Enanta Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
ENTAEnanta Pharmaceuticals3.4×
ARVNArvinas0.8×
NATRNatures Sunshine Products1.3×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Enanta Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.